pamidronate has been researched along with Kahler Disease in 168 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 9.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 9.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 9.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 9.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 9.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma." | 9.10 | Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma. ( Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E, 2003) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 9.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma." | 9.08 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, H; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, M; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, JF, 1998) |
| "This study was performed as a cross-sectional substudy to the Danish-Swedish Pamidronate Study, a randomized placebo-controlled multicentre trial in multiple myeloma." | 9.08 | Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. ( Abildgaard, N; Brincker, H; Brixen, K; Eriksen, EF; Glerup, H; Heickendorff, L; Kassem, M; Nielsen, JL; Rungby, J, 1998) |
| "We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner." | 8.83 | Scleritis complicating zoledronic acid infusion. ( Badros, A; Benderson, D; Karakunnel, J; Kathuria, S, 2006) |
| "Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications." | 7.81 | Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. ( Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K, 2015) |
| "It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease." | 7.78 | In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2012) |
| "Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates." | 7.75 | [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. ( Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A, 2009) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 7.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 7.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 7.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 7.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| "Amino-biphosphonates (like pamidronate) activate human Vgamma9/Vdelta2 T lymphocytes and promote their cytotoxicity against multiple myeloma cells." | 7.73 | MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. ( Belloni, D; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Fortis, C; Girlanda, S; Groh, V; Sciorati, C; Spies, T; Ticozzi, P; Tresoldi, M; Vicari, A, 2005) |
| "We investigated the anti-tumor effect of pamidronate after obtaining a decrease of serum monoclonal immunoglobulin (Ig) level by conventional chemotherapy in patients with multiple myeloma (MM) in order to evaluate whether the drug is useful as maintenance therapy for MM." | 7.72 | Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma. ( Kondo, H; Kubota, M; Mori, A, 2003) |
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 7.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| "We report a patient with multiple myeloma who was treated with pamidronate disodium every 3 weeks for 18 months without any other chemotherapeutic agents." | 7.71 | Anti-tumor activity of pamidronate in human multiple myeloma. ( Kondo, H; Mori, A, 2002) |
| "Anti-resorptive bisphosphonates, such as pamidronate, are an effective treatment for osteolytic disease and hypercalcaemia in patients with multiple myeloma, but have also been shown to cause apoptosis of myeloma cell lines in vitro." | 7.71 | Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. ( Culligan, DJ; Gordon, S; Greaves, M; Helfrich, MH; Ralston, SH; Rogers, MJ; Sati, HI; Soutar, RL, 2002) |
| "Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3." | 7.71 | Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. ( Desikan, R; Jagannath, S; Li, ZJ; Raza, S; Sabir, T; Stokes, B; Veksler, Y, 2002) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 7.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 6.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 6.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 6.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 6.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| "Pamidronate was administered at a monthly dose of 90 mg iv, and the above parameters were evaluated at the beginning of this study and after 1, 3, 6, 9, 12 and 14 months of treatment." | 6.69 | Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. ( Anargyrou, K; Meletis, J; Palermos, J; Papassavas, P; Terpos, E; Tsionos, K; Viniou, N; Yataganas, X, 2000) |
| " Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures." | 6.18 | Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997) |
| "Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases." | 5.31 | Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. ( Appel, GB; D'Agati, VD; Dratch, AD; Fenves, AZ; Fine, PL; Jagannath, S; Kuhn, JA; Loon, NR; Markowitz, GS, 2001) |
| "Addition of bisphosphonates to standard treatment of multiple myeloma (MM) decreases bone pain and skeletal events without influencing bone healing." | 5.30 | Effect of calcitriol and pamidronate in multiple myeloma. ( Holbert, JM; Imseis, RE; Leventhal, MR; Palmieri, GM; Sebes, JI, 1999) |
| " Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years." | 5.14 | Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 5.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 5.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 5.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| " To evaluate the antitumor activity of gammadelta T cells in vivo, we initiated a pilot study of low-dose interleukin 2 (IL-2) in combination with pamidronate in 19 patients with relapsed/refractory low-grade non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)." | 5.10 | Gammadelta T cells for immune therapy of patients with lymphoid malignancies. ( Eckstein, S; Kunzmann, V; Reimer, P; Ruediger, T; Tony, HP; Weissinger, F; Wilhelm, M, 2003) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 5.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| "Thalidomide is active both as single agent and in combination-therapy against refractory or relapsing multiple myeloma." | 5.10 | Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma. ( Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E, 2003) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Twelve patients with smouldering or indolent multiple myeloma (MM) received 12 courses of intravenous pamidronate as a single agent to evaluate both the antitumour and bone metabolism effects." | 5.10 | Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. ( Bladé, J; Fernández-Calvo, J; García-Sanz, R; González, M; Hernández, J; Martín, A; Mateo, G; Orfao, A; San Miguel, JF; Suquía, B, 2002) |
| "In the first year of treatment monthly intravenous pamidronate administration as an adjunct to chemotherapy in patients with advanced multiple myeloma with osteolysis is an efficient approach in prevention and treatment of hyperacalcaemia, hypercalciuria and bone pain." | 5.09 | Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. ( Kraj, M; Maj, S; Nasiłowska, B; Pawlikowski, J; Pogłód, R, 2000) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 5.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma." | 5.08 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, H; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, M; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, JF, 1998) |
| "This study was performed as a cross-sectional substudy to the Danish-Swedish Pamidronate Study, a randomized placebo-controlled multicentre trial in multiple myeloma." | 5.08 | Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. ( Abildgaard, N; Brincker, H; Brixen, K; Eriksen, EF; Glerup, H; Heickendorff, L; Kassem, M; Nielsen, JL; Rungby, J, 1998) |
| "Zoledronic acid seems to be the most efficacious bisphosphonate for reducing the risk of SREs in patients with cancer of the breast or prostate and those with multiple myeloma." | 4.89 | Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. ( Brown, J; Fullarton, JR; Palmieri, C, 2013) |
| ", oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM." | 4.87 | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. ( Berenson, J; Dimopoulos, MA; Terpos, E, 2011) |
| "Zoledronic acid and pamidronate are two potent anticatabolic nitrogen-containing bisphosphonates (BPs) used extensively in diseases with high bone turnover such as multiple myeloma (MM)." | 4.87 | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. ( Pozzi, S; Raje, N, 2011) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| "We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner." | 4.83 | Scleritis complicating zoledronic acid infusion. ( Badros, A; Benderson, D; Karakunnel, J; Kathuria, S, 2006) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| "Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications." | 3.81 | Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. ( Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K, 2015) |
| "We studied markers of bone turnover over a 6-month period after a single dose of zoledronic acid in 29 patients with multiple myeloma in remission who previously received 8 to 12 doses of pamidronate or zoledronate (NCT00577642)." | 3.80 | Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. ( Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ, 2014) |
| "No anabolic drugs are currently approved to treat multiple myeloma (MM)-induced bone disease and the anti-MM agent bortezomib exhibits the anabolic effects in the clinic." | 3.79 | In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2013) |
| "It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease." | 3.78 | In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease. ( Lin, B; Wang, Y, 2012) |
| "Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates." | 3.75 | [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. ( Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A, 2009) |
| " The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency." | 3.74 | A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 3.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| "Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration." | 3.74 | Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 3.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| "Amino-biphosphonates (like pamidronate) activate human Vgamma9/Vdelta2 T lymphocytes and promote their cytotoxicity against multiple myeloma cells." | 3.73 | MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. ( Belloni, D; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Fortis, C; Girlanda, S; Groh, V; Sciorati, C; Spies, T; Ticozzi, P; Tresoldi, M; Vicari, A, 2005) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| " We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively." | 3.73 | [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis]. ( Gregersen, H; Neumann, B, 2006) |
| " Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures." | 3.73 | [Osteonecrosis associated with the use of biphosphonates: Case report]. ( Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I, 2006) |
| "We investigated the anti-tumor effect of pamidronate after obtaining a decrease of serum monoclonal immunoglobulin (Ig) level by conventional chemotherapy in patients with multiple myeloma (MM) in order to evaluate whether the drug is useful as maintenance therapy for MM." | 3.72 | Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma. ( Kondo, H; Kubota, M; Mori, A, 2003) |
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 3.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| " Treatment of OVX 5T2MM mice with pamidronate reduced osteolysis but had little effect on the time development of the tumor." | 3.72 | Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. ( Baslé, MF; Bataille, R; Chappard, D; Libouban, H; Moreau, MF, 2003) |
| "Pamidronate has been mainly associated with collapsing focal segmental glomerulosclerosis." | 3.72 | Podocyte injury associated glomerulopathies induced by pamidronate. ( Abulezz, SR; Barri, YM; Bonsib, SM; Munshi, NC; Sukumalchantra, S; Walker, PD; Wallach, J, 2004) |
| "We report a patient with multiple myeloma who was treated with pamidronate disodium every 3 weeks for 18 months without any other chemotherapeutic agents." | 3.71 | Anti-tumor activity of pamidronate in human multiple myeloma. ( Kondo, H; Mori, A, 2002) |
| "Anti-resorptive bisphosphonates, such as pamidronate, are an effective treatment for osteolytic disease and hypercalcaemia in patients with multiple myeloma, but have also been shown to cause apoptosis of myeloma cell lines in vitro." | 3.71 | Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. ( Culligan, DJ; Gordon, S; Greaves, M; Helfrich, MH; Ralston, SH; Rogers, MJ; Sati, HI; Soutar, RL, 2002) |
| "Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3." | 3.71 | Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. ( Desikan, R; Jagannath, S; Li, ZJ; Raza, S; Sabir, T; Stokes, B; Veksler, Y, 2002) |
| "Patients with multiple myeloma and other forms of cancer receiving pamidronate via intravenous (IV) infusion at the Hamilton Regional Cancer Centre in Hamilton, Ontario, Canada face 2 treatment options: they can have their entire treatment completed at the clinic using traditional IV therapy (e." | 3.71 | Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. ( Broadfield, L; Coyte, PC; Dobrow, MJ, 2001) |
| "In a double blind randomized study, the bisphosphonate drug Pamidronate (Aredia) significantly protected Durie-Salmon stage III multiple myeloma patients from osteolytic bone disease." | 3.70 | In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. ( Aparicio, A; Berenson, J; Gardner, A; Lichtenstein, A; Savage, A; Tu, Y, 1998) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| " We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients)." | 3.68 | [Disodium pamidronate (APD) in the treatment of bone metastases]. ( Costa, L; da Costa, EB; Moreira, C, 1993) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 3.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| "dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days." | 2.72 | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. ( Bekker, PJ; Body, JJ; Coleman, RE; Facon, T; Fan, M; Geurs, F; Holloway, D; Lipton, A; Peterson, MC, 2006) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 2.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 2.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease." | 2.70 | Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. ( Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ, 2001) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 2.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 2.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| "Pamidronate was administered at a monthly dose of 90 mg iv, and the above parameters were evaluated at the beginning of this study and after 1, 3, 6, 9, 12 and 14 months of treatment." | 2.69 | Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. ( Anargyrou, K; Meletis, J; Palermos, J; Papassavas, P; Terpos, E; Tsionos, K; Viniou, N; Yataganas, X, 2000) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "Collapsing focal segmental glomerulosclerosis is well described in its idiopathic form, mostly seen in young African American patients, and in association with HIV virus." | 2.45 | [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review]. ( Jotterand, V; Martin, PY; Moll, S; Saudan, P, 2009) |
| "Hypocalcemia was treated with calcium and vitamin D3 supplements." | 2.44 | [Zoledronate-associated end stage renal failure and hypocalcaemia]. ( Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y, 2007) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "The major clinical manifestations of multiple myeloma are related to the loss of bone." | 2.41 | Advances in the biology and treatment of myeloma bone disease. ( Berenson, JR, 2002) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures." | 2.41 | Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000) |
| "Multiple myeloma is a clonal B-cell tumor of slowly proliferating plasma cells within the bone marrow." | 2.41 | Multiple myeloma: present and future. ( Hussein, MA; Juturi, JV; Lieberman, I, 2002) |
| "Progressive multiple myeloma may manifest features of 'de-differentiation', including a plasmablastic appearance, failure to secrete paraprotein, extramedullary involvement, and resistance to treatment." | 2.41 | Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation. ( Balmaceda, C; Mansukhani, M; Mears, JG; Orazi, A; Rescigno, J; Savage, DG; Shendrik, I, 2002) |
| "Future progress in treating multiple myeloma NRC depends on better identification of new therapeutic targets that control progression from the stable asymptomatic to the progressive symptomatic phase of multiple myeloma." | 2.41 | Smoldering, asymptomatic stage 1, and indolent myeloma. ( Greipp, PR, 2000) |
| "Experts in the field were approached." | 2.40 | Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998) |
| "This is particularly true in multiple myeloma (MM), where bone involvement markedly influences the quality of life of patients." | 2.40 | The role of bisphosphonates for the treatment of bone disease in multiple myeloma. ( Musto, P, 1998) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "In this cohort study, patients with multiple myeloma (MM) on intravenous BP therapy were enrolled over 1 year." | 1.37 | Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. ( Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D, 2011) |
| " Long term use of bisphosphonates has recently been associated with osteonecrosis of the jaw (ONJ) defined as a three month non-healing defect in the jaw." | 1.36 | Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. ( Cevreska, L; Jovanovic, R; Karanfilski, O; Pavkovic, M; Petrushevska, G; Stankovic, S; Stojanovic, A, 2010) |
| "Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables." | 1.35 | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "Multiple myeloma was the most common comorbidity." | 1.34 | Bisphosphonates and jaw osteonecrosis: the UAMS experience. ( Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E, 2007) |
| "Over last 10 years, cases of jaw bone necrosis have been associated with the use of bisphosphonate therapy." | 1.33 | Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. ( Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P, 2005) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient." | 1.33 | Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "A patient with multiple myeloma who developed hypercalcemia during three different stages of his disease, with a different hypercalcemic agent elevated in his serum on each occasion, is described." | 1.32 | Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. ( Bergi-Stamatelou, M; Karga, H; Papapetrou, PD; Thanou, S, 2003) |
| "Neovascularisation and bone resorption are related to myeloma disease activity." | 1.32 | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. ( Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP, 2004) |
| "Pamidronate-treated bone marrow (BM) cultures of 24 patients with MM showed significantly reduced plasma cell survival compared with untreated cultures, especially in cultures in which activation of BM-gamma delta T cells was evident (14 of 24 patients with MM)." | 1.31 | Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. ( Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M, 2000) |
| "Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases." | 1.31 | Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. ( Appel, GB; D'Agati, VD; Dratch, AD; Fenves, AZ; Fine, PL; Jagannath, S; Kuhn, JA; Loon, NR; Markowitz, GS, 2001) |
| "Addition of bisphosphonates to standard treatment of multiple myeloma (MM) decreases bone pain and skeletal events without influencing bone healing." | 1.30 | Effect of calcitriol and pamidronate in multiple myeloma. ( Holbert, JM; Imseis, RE; Leventhal, MR; Palmieri, GM; Sebes, JI, 1999) |
| "The association of leukemia and multiple myeloma is well described usually as a complication of chemotherapy but also in the absence of chemotherapy or at diagnosis." | 1.30 | Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages. ( Dunkley, S; Gibson, J; Iland, H; Joshua, D; Li, C, 1999) |
| "MMP-2 is involved both in bone resorption and in the metastatic process." | 1.30 | Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. ( Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N, 1999) |
| "Cytostatic treatment of multiple myeloma in combination with repetitive i." | 1.29 | Reversible metastatic pulmonary calcification in a patient with multiple myeloma. ( Frickhofen, N; Friedrich, JM; Hoffmeister, A; Mattfeldt, T; Merkle, E; Prümmer, O; Weber, CK, 1996) |
| "The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM." | 1.27 | Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. ( Bijvoet, OL; Brondijk, RJ; Croese, JW; Haaijman, JJ; Kazil, M; Radl, J; Reitsma, PH; van den Enden-Vieveen, MH; Zurcher, C, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.19) | 18.7374 |
| 1990's | 35 (20.83) | 18.2507 |
| 2000's | 100 (59.52) | 29.6817 |
| 2010's | 30 (17.86) | 24.3611 |
| 2020's | 1 (0.60) | 2.80 |
| Authors | Studies |
|---|---|
| Shulman, R | 1 |
| Geara, AS | 1 |
| Berns, JS | 1 |
| Mhaskar, R | 2 |
| Kumar, A | 2 |
| Miladinovic, B | 2 |
| Djulbegovic, B | 2 |
| Chen, Y | 2 |
| Sebag, M | 1 |
| Powell, TI | 1 |
| Morin, SN | 1 |
| Leng, S | 1 |
| Tsai, WY | 1 |
| Bhutani, D | 1 |
| Hillyer, GC | 1 |
| Lim, E | 1 |
| Accordino, MK | 1 |
| Wright, JD | 1 |
| Hershman, DL | 1 |
| Lentzsch, S | 2 |
| Neugut, AI | 1 |
| Wang, Y | 2 |
| Lin, B | 2 |
| Terpos, E | 10 |
| Morgan, G | 1 |
| Dimopoulos, MA | 6 |
| Drake, MT | 1 |
| Raje, N | 2 |
| Sezer, O | 1 |
| García-Sanz, R | 2 |
| Shimizu, K | 1 |
| Turesson, I | 3 |
| Reiman, T | 1 |
| Jurczyszyn, A | 1 |
| Merlini, G | 1 |
| Spencer, A | 1 |
| Leleu, X | 1 |
| Cavo, M | 1 |
| Munshi, N | 1 |
| Rajkumar, SV | 3 |
| Durie, BG | 2 |
| Roodman, GD | 1 |
| Soydan, SS | 1 |
| Uckan, S | 1 |
| Palmieri, C | 1 |
| Fullarton, JR | 1 |
| Brown, J | 1 |
| Alegre, A | 1 |
| Gironella, M | 1 |
| Bailén, A | 1 |
| Giraldo, P | 1 |
| Sanfilippo, KM | 1 |
| Gage, B | 1 |
| Luo, S | 1 |
| Weilbaecher, K | 1 |
| Tomasson, M | 1 |
| Vij, R | 1 |
| Colditz, G | 1 |
| Carson, K | 1 |
| Patel, CG | 1 |
| Yee, AJ | 1 |
| Scullen, TA | 1 |
| Nemani, N | 1 |
| Santo, L | 1 |
| Richardson, PG | 1 |
| Laubach, JP | 1 |
| Ghobrial, IM | 1 |
| Schlossman, RL | 1 |
| Munshi, NC | 3 |
| Anderson, KC | 1 |
| Raje, NS | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Papamerkouriou, YM | 1 |
| Kenanidis, E | 1 |
| Gamie, Z | 1 |
| Papavasiliou, K | 1 |
| Kostakos, T | 1 |
| Potoupnis, M | 1 |
| Sarris, I | 1 |
| Tsiridis, E | 1 |
| Kyrkos, J | 1 |
| Barlogie, B | 3 |
| van Rhee, F | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 2 |
| Yaccoby, S | 2 |
| Pineda-Roman, M | 1 |
| Hollmig, K | 1 |
| Alsayed, Y | 1 |
| Hoering, A | 1 |
| Szymonifka, J | 1 |
| Anaissie, E | 1 |
| Petty, N | 1 |
| Kumar, NS | 1 |
| Srivastava, G | 1 |
| Jenkins, B | 1 |
| Crowley, J | 2 |
| Zeldis, JB | 1 |
| Dong, M | 1 |
| Feng, FY | 1 |
| Zhang, Y | 1 |
| Xie, GR | 1 |
| Wang, YJ | 1 |
| Liu, JW | 1 |
| Song, ST | 1 |
| Zhou, QH | 1 |
| Ren, J | 1 |
| Jiao, SC | 1 |
| Li, J | 1 |
| Wang, XW | 1 |
| Chen, Q | 1 |
| Wang, ZH | 1 |
| Xu, N | 1 |
| Feng, JF | 1 |
| Jotterand, V | 1 |
| Moll, S | 1 |
| Martin, PY | 1 |
| Saudan, P | 1 |
| Lund, T | 1 |
| Gregersen, H | 3 |
| Vangsted, A | 2 |
| Marker, P | 1 |
| Abildgaard, N | 4 |
| Vahtsevanos, K | 2 |
| Kyrgidis, A | 1 |
| Verrou, E | 2 |
| Katodritou, E | 1 |
| Triaridis, S | 1 |
| Andreadis, CG | 1 |
| Boukovinas, I | 1 |
| Koloutsos, GE | 1 |
| Teleioudis, Z | 2 |
| Kitikidou, K | 1 |
| Paraskevopoulos, P | 1 |
| Zervas, K | 2 |
| Antoniades, K | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Berenson, J | 5 |
| Cook, RJ | 2 |
| Lipton, A | 13 |
| Coleman, RE | 8 |
| Skamene, S | 1 |
| Rotondo, RL | 1 |
| Shustik, C | 1 |
| Roberge, D | 1 |
| Gimsing, P | 2 |
| Carlson, K | 1 |
| Fayers, P | 1 |
| Waage, A | 1 |
| Mylin, A | 1 |
| Gluud, C | 1 |
| Juliusson, G | 1 |
| Hjorth-Hansen, H | 1 |
| Nesthus, I | 1 |
| Dahl, IM | 1 |
| Westin, J | 2 |
| Nielsen, JL | 2 |
| Knudsen, LM | 1 |
| Ahlberg, L | 1 |
| Hjorth, M | 1 |
| Andersen, NF | 1 |
| Linder, O | 1 |
| Wisløff, F | 1 |
| Pavkovic, M | 1 |
| Petrushevska, G | 1 |
| Jovanovic, R | 1 |
| Karanfilski, O | 1 |
| Cevreska, L | 1 |
| Stankovic, S | 1 |
| Stojanovic, A | 1 |
| D'Arena, G | 1 |
| Gobbi, PG | 1 |
| Broglia, C | 1 |
| Sacchi, S | 1 |
| Quarta, G | 1 |
| Baldini, L | 1 |
| Iannitto, E | 1 |
| Falcone, A | 3 |
| Guariglia, R | 1 |
| Pietrantuono, G | 1 |
| Villani, O | 1 |
| Martorelli, MC | 1 |
| Mansueto, G | 1 |
| Sanpaolo, G | 3 |
| Cascavilla, N | 2 |
| Musto, P | 4 |
| Katz, J | 1 |
| Gong, Y | 1 |
| Salmasinia, D | 1 |
| Hou, W | 1 |
| Burkley, B | 1 |
| Ferreira, P | 1 |
| Casanova, O | 1 |
| Langaee, TY | 1 |
| Moreb, JS | 1 |
| Gertz, MA | 2 |
| Pozzi, S | 1 |
| Ludwig, H | 1 |
| Zojer, N | 1 |
| Berenson, JR | 9 |
| Shimizu, H | 1 |
| Monden, T | 1 |
| Tomotsune, T | 1 |
| Nakatani, Y | 1 |
| Domeki, N | 1 |
| Matsumura, M | 1 |
| Jojima, T | 1 |
| Kawagoe, Y | 1 |
| Kasai, K | 1 |
| Redzepovic, J | 1 |
| Wheatley, K | 1 |
| Clark, OA | 1 |
| Glasmacher, A | 1 |
| Hewson, I | 1 |
| Syme, D | 1 |
| Bruscino-Raiola, F | 1 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Kondo, H | 2 |
| Mori, A | 2 |
| Hillner, BE | 1 |
| Kyle, RA | 3 |
| Anderson, K | 1 |
| Yee, GC | 1 |
| Biermann, JS | 1 |
| Ferraro, G | 1 |
| Gordon, S | 1 |
| Helfrich, MH | 1 |
| Sati, HI | 1 |
| Greaves, M | 1 |
| Ralston, SH | 1 |
| Culligan, DJ | 1 |
| Soutar, RL | 2 |
| Rogers, MJ | 2 |
| Desikan, R | 1 |
| Veksler, Y | 1 |
| Raza, S | 1 |
| Stokes, B | 1 |
| Sabir, T | 1 |
| Li, ZJ | 1 |
| Jagannath, S | 2 |
| Small, E | 1 |
| Saad, F | 1 |
| Gleason, D | 1 |
| Gordon, D | 2 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 1 |
| Reitsma, D | 1 |
| Seaman, J | 4 |
| Leng, Y | 1 |
| Chen, SL | 1 |
| Shi, HZ | 1 |
| Saghafi, D | 1 |
| Body, JJ | 4 |
| Greipp, P | 1 |
| Facon, T | 4 |
| Geurs, F | 2 |
| Fermand, JP | 1 |
| Harousseau, JL | 3 |
| Mariette, X | 1 |
| Williams, CD | 1 |
| Nakanishi, A | 1 |
| Holloway, D | 2 |
| Martin, SW | 1 |
| Dunstan, CR | 1 |
| Bekker, PJ | 2 |
| Papapetrou, PD | 1 |
| Bergi-Stamatelou, M | 1 |
| Karga, H | 1 |
| Thanou, S | 1 |
| Wilhelm, M | 2 |
| Kunzmann, V | 2 |
| Eckstein, S | 1 |
| Reimer, P | 1 |
| Weissinger, F | 2 |
| Ruediger, T | 1 |
| Tony, HP | 2 |
| Viniou, N | 4 |
| de la Fuente, J | 2 |
| Meletis, J | 4 |
| Voskaridou, E | 1 |
| Karkantaris, C | 1 |
| Vaiopoulos, G | 2 |
| Palermos, J | 3 |
| Yataganas, X | 4 |
| Goldman, JM | 2 |
| Rahemtulla, A | 2 |
| Haidar, JH | 1 |
| Bazarbachi, A | 1 |
| Nasr, MR | 1 |
| El-Sabban, ME | 1 |
| Daher, R | 1 |
| Kubota, M | 1 |
| Szydlo, R | 1 |
| Hatjiharissi, E | 1 |
| Bodenizza, C | 2 |
| Carella, AM | 2 |
| Libouban, H | 1 |
| Moreau, MF | 1 |
| Baslé, MF | 1 |
| Bataille, R | 3 |
| Chappard, D | 1 |
| Rosen, LS | 2 |
| Kaminski, M | 1 |
| Howell, A | 2 |
| Belch, A | 1 |
| Mackey, J | 1 |
| Apffelstaedt, J | 1 |
| Hussein, MA | 2 |
| Reitsma, DJ | 3 |
| Chen, BL | 1 |
| Seaman, JJ | 2 |
| Melillo, L | 1 |
| Scalzulli, PR | 1 |
| Dell'Olio, M | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Caparrotti, G | 1 |
| Catalano, L | 1 |
| Feo, C | 1 |
| Vallone, R | 1 |
| Pagnini, D | 1 |
| Rotoli, B | 1 |
| Barri, YM | 1 |
| Sukumalchantra, S | 1 |
| Abulezz, SR | 1 |
| Bonsib, SM | 1 |
| Wallach, J | 1 |
| Walker, PD | 1 |
| Kunin, M | 1 |
| Kopolovic, J | 1 |
| Avigdor, A | 1 |
| Holtzman, EJ | 1 |
| Ma, M | 1 |
| Kyrtsonis, MC | 1 |
| Vassilakopoulos, TP | 1 |
| Siakantaris, MP | 1 |
| Kokoris, SI | 1 |
| Gribabis, DA | 1 |
| Dimopoulou, MN | 1 |
| Angelopoulou, MK | 1 |
| Pangalis, GA | 1 |
| Smith, AG | 1 |
| Schey, S | 1 |
| Andrews, CD | 1 |
| Baister, ER | 1 |
| Bilbrough, C | 1 |
| Connelly, M | 1 |
| Joyce, A | 1 |
| Child, JA | 1 |
| Díaz, C | 1 |
| Soutelo, MJ | 1 |
| Quiroga, L | 1 |
| Palmer, L | 1 |
| Lutfi, R | 1 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Reed, SD | 1 |
| Radeva, JI | 1 |
| Glendenning, GA | 1 |
| Schulman, KA | 1 |
| Chou, T | 1 |
| Carter, G | 1 |
| Goss, AN | 1 |
| Doecke, C | 1 |
| Katz, M | 1 |
| Girlanda, S | 1 |
| Fortis, C | 1 |
| Belloni, D | 1 |
| Ferrero, E | 1 |
| Ticozzi, P | 1 |
| Sciorati, C | 1 |
| Tresoldi, M | 1 |
| Vicari, A | 1 |
| Spies, T | 1 |
| Groh, V | 1 |
| Caligaris-Cappio, F | 1 |
| Ferrarini, M | 1 |
| Merigo, E | 2 |
| Manfredi, M | 2 |
| Meleti, M | 2 |
| Corradi, D | 2 |
| Vescovi, P | 2 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Henley, D | 1 |
| Kaye, J | 1 |
| Walsh, J | 1 |
| Cull, G | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Vastag, B | 1 |
| Pastor-Zuazaga, D | 1 |
| Garatea-Crelgo, J | 1 |
| Martino-Gorbea, R | 1 |
| Etayo-Pérez, A | 1 |
| Sebastián-López, C | 1 |
| Fan, M | 1 |
| Peterson, MC | 1 |
| Nasr, SH | 1 |
| Preddie, DC | 1 |
| Markowitz, GS | 3 |
| Appel, GB | 2 |
| D'Agati, VD | 3 |
| Klomp, CM | 1 |
| van den Broek, MW | 1 |
| Buijs, J | 1 |
| Beekman, R | 1 |
| Hay, KD | 1 |
| Bishop, PA | 1 |
| Dimitrakopoulos, I | 1 |
| Magopoulos, C | 1 |
| Karakasis, D | 1 |
| Migliorati, CA | 1 |
| Siegel, MA | 1 |
| Elting, LS | 1 |
| Bemardeschi, P | 1 |
| Dentico, P | 1 |
| Rossi, S | 1 |
| Fiorentini, G | 1 |
| Giustarini, G | 1 |
| Turano, E | 1 |
| Neumann, B | 1 |
| Attal, M | 1 |
| Leyvraz, S | 2 |
| Doyen, C | 1 |
| Hulin, C | 1 |
| Benboubker, L | 1 |
| Yakoub Agha, I | 1 |
| Bourhis, JH | 1 |
| Garderet, L | 1 |
| Pegourie, B | 1 |
| Dumontet, C | 1 |
| Renaud, M | 1 |
| Voillat, L | 1 |
| Berthou, C | 1 |
| Marit, G | 1 |
| Monconduit, M | 1 |
| Caillot, D | 1 |
| Grobois, B | 1 |
| Avet-Loiseau, H | 1 |
| Moreau, P | 1 |
| Banti, A | 1 |
| Mihou, D | 1 |
| Krikelis, D | 1 |
| Lacy, MQ | 1 |
| Dispenzieri, A | 1 |
| Greipp, PR | 2 |
| Gollbach, KL | 1 |
| Hayman, SR | 1 |
| Kumar, S | 1 |
| Lust, JA | 1 |
| Russell, SJ | 1 |
| Witzig, TE | 1 |
| Zeldenrust, SR | 1 |
| Dingli, D | 1 |
| Bergsagel, PL | 1 |
| Fonseca, R | 1 |
| Reeder, CB | 1 |
| Stewart, AK | 1 |
| Roy, V | 1 |
| Dalton, RJ | 1 |
| Carr, AB | 1 |
| Kademani, D | 1 |
| Keller, EE | 1 |
| Viozzi, CF | 1 |
| Trimarchi, H | 1 |
| Lombi, F | 1 |
| Forrester, M | 1 |
| Elizondo, C | 1 |
| Sawinski, D | 1 |
| Pereyra, H | 1 |
| Freixas, E | 1 |
| Wutzl, A | 1 |
| Eisenmenger, G | 1 |
| Hoffmann, M | 1 |
| Czerny, C | 1 |
| Moser, D | 1 |
| Pietschmann, P | 1 |
| Ewers, R | 1 |
| Baumann, A | 1 |
| Benderson, D | 1 |
| Karakunnel, J | 1 |
| Kathuria, S | 1 |
| Badros, A | 1 |
| Bains, MA | 1 |
| Pardoe, LE | 1 |
| Rudin, CE | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 2 |
| Treister, N | 1 |
| Woo, SB | 1 |
| de Lemos, ML | 1 |
| Taylor, SC | 1 |
| Barnett, JB | 1 |
| Hu, F | 1 |
| Levin, A | 1 |
| Moravan, V | 1 |
| O'Reilly, SE | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Anguita C, T | 1 |
| Agurto P, J | 1 |
| Roa E, I | 1 |
| Laissle C, G | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Zhang, PL | 1 |
| Quiery, AT | 1 |
| Blasick, TM | 1 |
| Brown, RE | 1 |
| Clarke, BM | 1 |
| Boyette, J | 1 |
| Vural, E | 1 |
| Suen, JY | 1 |
| Anaissie, EJ | 1 |
| Stack, BC | 1 |
| Corso, A | 2 |
| Varettoni, M | 1 |
| Zappasodi, P | 2 |
| Klersy, C | 1 |
| Mangiacavalli, S | 1 |
| Pica, G | 1 |
| Lazzarino, M | 1 |
| Ramazzina, C | 1 |
| Zysset Aschmann, Y | 1 |
| Kummer, O | 1 |
| Rätz Bravo, AE | 1 |
| Bodmer, M | 1 |
| Jadu, F | 1 |
| Lee, L | 1 |
| Pharoah, M | 1 |
| Reece, D | 1 |
| Wang, L | 2 |
| Major, P | 1 |
| Smith, MR | 1 |
| Vieillard, MH | 1 |
| Maes, JM | 1 |
| Penel, G | 1 |
| Magro, L | 1 |
| Bonneterre, J | 1 |
| Cortet, B | 1 |
| Murray, DJ | 1 |
| Vesely, MJ | 1 |
| Novak, CB | 1 |
| Irish, J | 1 |
| Crump, M | 1 |
| Neligan, PC | 1 |
| Bedogni, A | 1 |
| Blandamura, S | 1 |
| Lokmic, Z | 1 |
| Palumbo, C | 1 |
| Ragazzo, M | 1 |
| Ferrari, F | 1 |
| Tregnaghi, A | 1 |
| Pietrogrande, F | 1 |
| Procopio, O | 1 |
| Saia, G | 1 |
| Ferretti, M | 1 |
| Bedogni, G | 1 |
| Chiarini, L | 1 |
| Ferronato, G | 1 |
| Ninfo, V | 1 |
| Lo Russo, L | 1 |
| Lo Muzio, L | 1 |
| Nocini, PF | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Thürlimann, B | 1 |
| Morant, R | 1 |
| Jungi, WF | 1 |
| Radziwill, A | 1 |
| Costa, L | 2 |
| Moreira, C | 1 |
| da Costa, EB | 1 |
| Lichtenstein, A | 3 |
| Porter, L | 3 |
| Bordoni, R | 2 |
| George, S | 2 |
| Keller, A | 2 |
| Ballester, O | 2 |
| Kovacs, MJ | 1 |
| Blacklock, HA | 1 |
| Bell, R | 2 |
| Simeone, J | 1 |
| Heffernan, M | 2 |
| Knight, RD | 2 |
| Weber, CK | 1 |
| Friedrich, JM | 1 |
| Merkle, E | 1 |
| Prümmer, O | 1 |
| Hoffmeister, A | 1 |
| Mattfeldt, T | 1 |
| Frickhofen, N | 1 |
| Harvey, HA | 1 |
| Paterson, AH | 2 |
| Kanis, JA | 3 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Piccart, M | 1 |
| Adamietz, IA | 1 |
| Laakso, M | 1 |
| Jantunen, E | 1 |
| Shipman, CM | 1 |
| Apperley, JF | 1 |
| Russell, RG | 1 |
| Croucher, PI | 1 |
| Kovacs, M | 1 |
| Blacklock, H | 1 |
| Simeone, JF | 1 |
| Iggo, N | 1 |
| Winearls, CG | 1 |
| Davies, DR | 1 |
| Bloomfield, DJ | 1 |
| Goodnight, SH | 1 |
| Feinstein, DI | 1 |
| Aparicio, A | 1 |
| Gardner, A | 1 |
| Tu, Y | 1 |
| Savage, A | 1 |
| Brincker, H | 2 |
| Hedenus, M | 1 |
| Ford, J | 1 |
| Kandra, A | 1 |
| Seymour, JF | 1 |
| Rungby, J | 1 |
| Glerup, H | 1 |
| Brixen, K | 1 |
| Kassem, M | 1 |
| Heickendorff, L | 1 |
| Eriksen, EF | 1 |
| Dhodapkar, MV | 1 |
| Singh, J | 1 |
| Mehta, J | 1 |
| Fassas, A | 1 |
| Desikan, KR | 1 |
| Perlman, M | 1 |
| Bartl, R | 1 |
| Burckhardt, P | 2 |
| Delmas, PD | 1 |
| Diel, IJ | 1 |
| Fleisch, H | 1 |
| Mundy, GR | 1 |
| Rubens, RD | 1 |
| Dranitsaris, G | 1 |
| Imseis, RE | 1 |
| Palmieri, GM | 1 |
| Holbert, JM | 1 |
| Leventhal, MR | 1 |
| Sebes, JI | 1 |
| Astori, C | 1 |
| Orlandi, E | 1 |
| Arcaini, L | 1 |
| Bernasconi, C | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 2 |
| Dunkley, S | 1 |
| Gibson, J | 1 |
| Iland, H | 1 |
| Li, C | 1 |
| Joshua, D | 1 |
| Major, PP | 1 |
| Hortobagyi, G | 2 |
| Derenne, S | 1 |
| Amiot, M | 1 |
| Barillé, S | 1 |
| Collette, M | 1 |
| Robillard, N | 1 |
| Tricot, G | 1 |
| Bauer, E | 1 |
| Feurle, J | 1 |
| McCloskey, EV | 1 |
| Tsionos, K | 1 |
| Anargyrou, K | 1 |
| Papassavas, P | 1 |
| Takahashi, R | 1 |
| Shimazaki, C | 1 |
| Inaba, T | 1 |
| Okano, A | 1 |
| Hatsuse, M | 1 |
| Okamoto, A | 1 |
| Hirai, H | 1 |
| Ashihara, E | 1 |
| Nakagawa, M | 1 |
| Morley, W | 1 |
| Dreicer, R | 1 |
| Kuross, SA | 1 |
| Kraj, M | 1 |
| Pogłód, R | 1 |
| Pawlikowski, J | 1 |
| Maj, S | 1 |
| Nasiłowska, B | 1 |
| Fine, PL | 2 |
| Fenves, AZ | 1 |
| Loon, NR | 1 |
| Kuhn, JA | 1 |
| Dratch, AD | 1 |
| Ali, SM | 1 |
| Esteva, FJ | 1 |
| Harvey, H | 1 |
| Knight, R | 1 |
| Das, H | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| Coyte, PC | 1 |
| Dobrow, MJ | 1 |
| Broadfield, L | 1 |
| Ranaghan, L | 1 |
| Morrison, J | 1 |
| Juturi, JV | 1 |
| Lieberman, I | 1 |
| Pearse, RN | 1 |
| Johnson, CL | 1 |
| Choi, Y | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
| Savage, DG | 1 |
| Mears, JG | 1 |
| Balmaceda, C | 1 |
| Rescigno, J | 1 |
| Shendrik, I | 1 |
| Mansukhani, M | 1 |
| Orazi, A | 1 |
| Martín, A | 1 |
| Hernández, J | 1 |
| Bladé, J | 1 |
| Suquía, B | 1 |
| Fernández-Calvo, J | 1 |
| González, M | 1 |
| Mateo, G | 1 |
| Orfao, A | 1 |
| San Miguel, JF | 1 |
| Thiébaud, D | 1 |
| von Fliedner, V | 1 |
| Perey, L | 1 |
| Cornu, P | 1 |
| Thiébaud, S | 1 |
| Man, Z | 1 |
| Otero, AB | 1 |
| Rendo, P | 1 |
| Barazzutti, L | 1 |
| Sanchez Avalos, JC | 1 |
| Judson, I | 1 |
| Booth, F | 1 |
| Gore, M | 1 |
| McElwain, T | 1 |
| Sawyer, N | 1 |
| Newstead, C | 1 |
| Drummond, A | 1 |
| Newland, A | 1 |
| Cunningham, J | 1 |
| Radl, J | 1 |
| Croese, JW | 1 |
| Zurcher, C | 1 |
| van den Enden-Vieveen, MH | 1 |
| Brondijk, RJ | 1 |
| Kazil, M | 1 |
| Haaijman, JJ | 1 |
| Reitsma, PH | 1 |
| Bijvoet, OL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates[NCT00577642] | Phase 2 | 29 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.[NCT00376883] | Phase 3 | 500 participants | Interventional | 2000-01-31 | Completed | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.[NCT02439112] | 102 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response | |
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
35 reviews available for pamidronate and Kahler Disease
| Article | Year |
|---|---|
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2017 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; | 2013 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Iband | 2014 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; De | 2015 |
[Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Female; Fractures, Spontaneous | 2009 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinica | 2011 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple | 2011 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin | 2011 |
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion | 2011 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat | 2012 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; D | 2002 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2005 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically | 2006 |
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; O | 2006 |
Scleritis complicating zoledronic acid infusion.
Topics: Aged; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles | 2006 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; | 2007 |
Bisphosphonates and avascular necrosis of the mandible: case report and review of the literature.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Male; Mandibular Diseases; Middle Aged; Mu | 2008 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Bisphosphonate therapy in multiple myeloma.
Topics: Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Multiple Myeloma; Pamidronate | 1996 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence | 1998 |
Update in hematology.
Topics: Anemia; Anticoagulants; Antineoplastic Agents; Chemotherapy, Adjuvant; Diphosphonates; Female; Hepar | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
The role of bisphosphonates for the treatment of bone disease in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Remodeling; Clinical Trials as Topic; Clodronic Acid; Diphospho | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
New insights into role of microenvironment in multiple myeloma.
Topics: Antineoplastic Agents; Carrier Proteins; Cytokines; Diphosphonates; Glycoproteins; Humans; Membrane | 2000 |
Bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid | 2000 |
Myeloma--the therapeutic challenge.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Multiple Myeloma; Pamidronate; Randomized Controlled | 2000 |
Multiple myeloma: present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplant | 2002 |
Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Combined Modality Thera | 2002 |
Smoldering, asymptomatic stage 1, and indolent myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Diet Therapy; Dip | 2000 |
35 trials available for pamidronate and Kahler Disease
| Article | Year |
|---|---|
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diphosphonates; Disease Progression; Di | 2008 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collage | 2008 |
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2010 |
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Dis | 2011 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Drug Th | 2002 |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Dose-Respo | 2003 |
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Dose | 2003 |
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Topics: Acid Phosphatase; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Resorption; Co | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Perspective study on pamidronate in stage I multiple myeloma.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Multiple Myeloma; Neoplasm Staging; Pamidronate; Surv | 2003 |
[Clinical observation on effect of combined therapy of pamidronati sodium and shenfu injection in treating multiple myeloma caused ostealgia].
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Diphosphonates; Drug Therapy, Combination; Drugs, Ch | 2004 |
Home care versus hospital care in patients with multiple myeloma treated with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Attitude to Health; Cross-Over Studies; Dipho | 2004 |
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area | 2006 |
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedim | 2003 |
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Diphosphonates; Disease-Free Su | 2006 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Cre | 2007 |
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
Topics: Activities of Daily Living; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relation | 1994 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Topics: Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Spontaneous; H | 1998 |
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bo | 1998 |
Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
Topics: Antineoplastic Agents; Attitude to Health; Canada; Cost-Benefit Analysis; Diphosphonates; Fractures, | 1999 |
Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bi | 2000 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neop | 2001 |
Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Male; Middle Aged; Multiple M | 2000 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imid | 2001 |
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta | 2001 |
Phase II trial of clarithromycin and pamidronate therapy in myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Clarithromycin; Diphosphonates | 2001 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
Topics: Aged; Bone Remodeling; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Infus | 2002 |
Use of pamidronate for multiple myeloma osteolytic lesions.
Topics: Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Multiple My | 1990 |
99 other studies available for pamidronate and Kahler Disease
| Article | Year |
|---|---|
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2022 |
Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Humans; Middle Aged; Mu | 2018 |
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A | 2019 |
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulat | 2013 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combin | 2013 |
Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Blood Platelets; Diphosphonates; Fibrin; H | 2014 |
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness R | 2015 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hy | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinica | 2010 |
Necrosis following skull base irradiation and stem cell transplant for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cranial Irradiation; Dexamethasone; Diphosphonates; | 2010 |
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Cli | 2010 |
Zoledronic acid in myeloma: MRC Myeloma IX.
Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodr | 2010 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates | 2010 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collag | 2011 |
The role of bisphosphonate therapy in the global management of multiple myeloma.
Topics: Diphosphonates; Humans; Multiple Myeloma; Pamidronate | 2011 |
A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Calcitonin; Calciu | 2011 |
Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Collagen Type | 2012 |
In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Diseases; Calibration | 2012 |
Anti-tumor activity of pamidronate in human multiple myeloma.
Topics: Aged; beta 2-Microglobulin; Diphosphonates; Female; Humans; Immunoglobulin G; Multiple Myeloma; Pami | 2002 |
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Multiple Myeloma; Osteolysis; P | 2002 |
Geraldine Ferraro. The fight of her life. Interview by Jo Cavallo.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Humans; Immunosuppressive Agents; Multiple Myel | 2002 |
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Diphosphonates; Female; Humans; Imidazole | 2002 |
Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
Topics: Antineoplastic Agents; Bence Jones Protein; Creatinine; Diphosphonates; Drug Administration Schedule | 2002 |
Use of bisphosphonates in patients with myeloma and renal failure.
Topics: Antineoplastic Agents; Bone Remodeling; Chronic Kidney Disease-Mineral and Bone Disorder; Contraindi | 2003 |
Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein.
Topics: Adult; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Diphosphonates; Humans; Hyperc | 2003 |
Signet ring-like light chain myeloma with systemic spread.
Topics: Anemia; Antineoplastic Agents; Bone Marrow Examination; Combined Modality Therapy; Diagnostic Errors | 2003 |
Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexam | 2003 |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chem | 2003 |
Pamidronate for early-stage, untreated myeloma.
Topics: Antineoplastic Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedul | 2003 |
Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.
Topics: Animals; Antineoplastic Agents; Bone Remodeling; Cell Division; Diphosphonates; Female; Femur; Mice; | 2003 |
Podocyte injury associated glomerulopathies induced by pamidronate.
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis | 2004 |
Treatment strategies for myeloma bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonanc | 2003 |
Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.
Topics: Antineoplastic Agents; Basement Membrane; Diphosphonates; Female; Glomerulosclerosis, Focal Segmenta | 2004 |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2004 |
[Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Injec | 2004 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; | 2005 |
MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Histocompatibility Antigens | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphon | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosph | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
Consumer groups look to improve adverse event reporting systems.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Co | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce | 2006 |
Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes.
Topics: Acute Kidney Injury; Albumins; Bone Density Conservation Agents; Bone Diseases, Metabolic; Creatinin | 2006 |
[Reversible posterior leucoencephalopathy due to hypercalcaemia].
Topics: Antineoplastic Agents; Blindness, Cortical; Brain Diseases; Cognition Disorders; Diagnosis, Differen | 2006 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, T | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mult | 2006 |
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Jaw Diseases; Male; M | 2006 |
Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Middle | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fol | 2006 |
Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Diphosphonates; Female; Humans; Hyperparathyroidism, Secon | 2007 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |
Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw.
Topics: Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorh | 2006 |
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Crea | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.
Topics: Alkyl and Aryl Transferases; Biomarkers; Cell Proliferation; Diphosphonates; Farnesyltranstransferas | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Inc | 2007 |
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
Topics: Diphosphonates; Humans; Incidence; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Radio | 2007 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; M | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphospho | 2008 |
[Disodium pamidronate (APD) in the treatment of bone metastases].
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Middle Aged; Multiple Myeloma; Pain | 1993 |
Management of myeloma with bisphosphonates.
Topics: Diphosphonates; Humans; Multiple Myeloma; Osteolysis; Pamidronate | 1996 |
Reversible metastatic pulmonary calcification in a patient with multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Calcinosis; Diphosphonates; Fema | 1996 |
Pamidronate disodium reduces skeletal complications of multiple myeloma.
Topics: Bone Diseases; Diphosphonates; Fractures, Spontaneous; Humans; Multiple Myeloma; Osteolysis; Pamidro | 1996 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
Topics: Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Multiple Myeloma; Osteoblasts; Pa | 1996 |
[The efficacy of pamidronate in reducing skeletal associated events in patients with advanced multiple myeloma].
Topics: Diphosphonates; Fractures, Spontaneous; Humans; Infusions, Intravenous; Multiple Myeloma; Pamidronat | 1997 |
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Topics: Apoptosis; Clodronic Acid; Diphosphonates; DNA, Neoplasm; Humans; Multiple Myeloma; Pamidronate; Tum | 1997 |
The development of cast nephropathy in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bence Jones Protein; Diphosphonates; Fluid Therapy; Humans; Immunoglobu | 1997 |
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Division; Cell Survival; Chelating Agent | 1998 |
Long-term pamidronate in multiple myeloma.
Topics: Antineoplastic Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Male; Multiple Myelom | 1998 |
Anti-myeloma activity of pamidronate in vivo.
Topics: Aged; Bone Marrow; Diphosphonates; Humans; Immunoglobulin G; Male; Middle Aged; Multiple Myeloma; Pa | 1998 |
Effect of calcitriol and pamidronate in multiple myeloma.
Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Calcitriol; Calcium Channel Agonists; Diphosph | 1999 |
Transient response of myeloma clone to pamidronate therapy.
Topics: Adult; Antineoplastic Agents; Diphosphonates; Humans; Male; Multiple Myeloma; Pamidronate | 1999 |
Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; | 1999 |
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division | 2000 |
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Diphosphonates; Flow Cytometry; Humans; Imidazoles; | 2001 |
Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis, Focal Seg | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.
Topics: Aged; Ambulatory Care; Anti-Inflammatory Agents; Costs and Cost Analysis; Diphosphonates; Female; Ho | 2001 |
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Topics: Animals; Bone Marrow Cells; Bone Transplantation; Cell Division; Diphosphonates; Humans; Imidazoles; | 2002 |
Nephrotic syndrome after treatment with pamidronate.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies | 2002 |
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; D | 1991 |
Chronic high-dose pamidronate in refractory malignant hypercalcaemia.
Topics: Diphosphonates; Drug Tolerance; Humans; Hypercalcemia; Male; Middle Aged; Multiple Myeloma; Pamidron | 1990 |
One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Diphosphonates; Drug Administration Schedule; | 1989 |
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Diphosphonates; Male; Mice; Mice, Inbred C57BL | 1985 |